APSR2026-1084

 
Late-Breaking
Submitted
Oral Presentation
AO35-006
 
 
 
Format: PPTX Only
 
Format: PDF Only
14. Respiratory Structure and Function
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jane Bourke * Monash University Pharmacology, Biomedicine Discovery Institute Clayton Australia
Julia Chitty - Monash University Pharmacology, Biomedicine Discovery Institute Clayton Australia
Olivia Young - Monash University Pharmacology, Biomedicine Discovery Institute Clayton Australia
Philip Bardin - Hudson Institute of Medical Research Centre for Innate Immunity and Infectious Diseases Clayton Australia
Yi Chen - Monash Health 3Monash Lung, Sleep, Allergy and Immunology Clayton Australia
Robert Widdop - Monash University Pharmacology, Biomedicine Discovery Institute Clayton Australia
Belinda Thomas - Hudson Institute of Medical Research Centre for Innate Immunity and Infectious Diseases Clayton Australia
 
 
 
 
 
 
 
 
Presenting Author Details
Jane
Bourke
jane.bourke@monash.edu
+61439348877
61-70
Australia
Original Research
Novel ex vivo models of COPD using mouse and human precision-cut lung slices
Maximum 25 words
Abstract Content
Experimental models that recapitulate or retain the major phenotypic characteristics of COPD are crucial for studying disease mechanisms and testing therapeutics. Precision-cut lung slices, which retain lung architecture and resident cells, provide an innovative approach for disease modelling. Our aim was to establish whether emphysema could be established ex vivo in elastase-treated mouse PCLS and to assess their responses to COPD-relevant inflammatory and fibrotic mediators in comparison with human PCLS from non-COPD and COPD lung.
Matched PCLS were prepared from (1) naïve C57Bl/6 mice (mPCLS: control (C); treated with 2.5 ng/ml elastase overnight (E)) and (2) healthy margins of human lung cancer resections (hPCLS: non-COPD; COPD). PCLS were then left untreated or treated for 5 days with fibrotic cocktail (FC): 5 ng/mL TGFβ1; 5 μM PDGF; 10 ng/mL TNFα; 5 μM LPA. mPCLS were analysed for structural and remodelling gene expression (RT-PCR); collagen deposition measured in mPCLS and hPCLS in situ (Massons trichrome staining); conditioned media assayed for procollagen 1α1 and inflammatory cytokines (ELISA).
In mPCLS, elastase increased mean linear intercept 1.3-fold and reduced alveolar markers (Aqp5, Sftpc, Rage) (p<0.05, n=6-10). Elastase and FC independently and additively increased KC (mouse IL-8 analogue), MCP-1 and Muc5b expression. FC increased Col1a1 gene expression in mPCLS and induced a 30% increase in collagen deposition in hPCLS from COPD but not non-COPD lung. Procollagen 1α1 levels in COPD PCLS media were higher at baseline and 75% higher with FC (COPD vs non-COPD, 283.9 vs 163.8 ng/mL, n=7,11, p<0.05). FC significantly increased IL-6 and IL-8 (non-stratified, n=6,11).
This novel mPCLS model recapitulates COPD phenotypes of emphysema and remodelling. We report for the first time that fibrotic responses are increased in hPCLS from COPD lung. These validated models offer relatively high throughout platforms for future applications that can be extended to COPD exacerbations and drug screening. .
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
COPD, precision-cut lung slice, model
maximum 3 keywords and no abbreviations, separated by commas
Funded by NHMRC (2021687), Monash Lung Sleep Institute No disclosures
322